Drug intelligence / Profile preview

reRNA-EGF vaccine

Development stage: Unknown
Lead developer: Jiangsu Leeway Biological Technology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

The reRNA-EGF vaccine is an RNA-based therapeutic vaccine developed by Jiangsu Leeway Biological Technology Co.Ltd. It is designed to treat non-small cell lung cancer by inducing an immune response against Epidermal Growth Factor (EGF). The vaccine aims to generate antibodies that target and neutralize circulating EGF, thereby preventing it from binding to its receptor, Epidermal Growth Factor Receptor (EGFR), on cancer cells. This mechanism is intended to inhibit EGF-mediated signaling pathways that promote tumor cell proliferation, survival, and metastasis.

Other names: reRNA-EGF 疫苗

Beyond the preview

Go deeper on reRNA-EGF vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on reRNA-EGF vaccine.

Explore the full profile